Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau(Institut Curie), Jean-Pierre Delord(Institut Claudius Regaud), Anthony Gonçalvès(Institut Paoli-Calmettes), Céline Gavoille(Délégation Centre-Est), Coraline Dubot(Institut Curie), Nicolás Isambert(Centre Georges François Leclerc), Mario Campone(Centre Hospitalier René-Dubos), Olivier Trédan(Centre Léon Bérard), M.A. Massiani(Hôpital Foch), Cécile Mauborgne(Institut Curie), Sébastien Armanet(Institut Curie), Nicolas Servant(Inserm), Ivan Bièche(Institut Curie), Virginie Bernard(Institut Curie), David Gentien(Institut Curie), Pascal Jézéquel, Valéry Attignon(Centre Léon Bérard), Sandrine Boyault(Centre Léon Bérard), Anne Vincent‐Salomon(Institut Curie), Vincent Servois(Institut Curie), Marie-Paule Sablin(Institut Curie), Maud Kamal(Institut Curie), Xavier Paolettí(Inserm)
Cited by 1,113
Abstract
Related Papers
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al.|New England Journal of Medicine|2005|5.1k